Advances in research on Rotavin-M1

Abstract

“Rotavin-M1” is an oral live-attenuated vaccine that prevents diarrhea in children under five years old, produced from rotavirus strains G1P [1] on Vero cells. This vaccine has been studied for 16 years beginning with monitoring the local circulating strain and eventually establishing a seed lots system. The safety and immunogenicity of the vaccine were found equivalent to internationally-imported vaccines

Overview of the Development, Impacts, and Challenges of Live-Attenuated Oral Rotavirus Vaccines

“…A broader analysis showed that the A antigen might be involved in the crossspecies transmission of rotavirus because of its ability to bind sialidase-sensitive and non-sialidase- A report has shown that strains like P [6] and P [11] have an age-specific host range with the ability of inter-species transmission. This feature is also found in serotypes like P [1], P [2], P [3], P [7], P [9], P [10], P [12], P [14], P [19], P [24], P [25], and P [28], which bind the A antigen in an oligosaccharide binding assay [274,277] (Table 4). These are possible because of the shared HBGAs ligands between humans and animals and perhaps a single evolutionary trend with a common ancestor with an animal host origin [274].…”

“…However, the use of these recently licensed rotavirus vaccines is still largely restricted to India and partly Africa; perhaps the focus is on the LMICs. Apart from these, there are other regionally licensed, LAORoVs such as LLR-37 from Lanzhou Biologicals (Chengguan District, Lanzhou, Gansu, China) or Xinkexian Biological Technology (Fuyang, Anhui, China) [ 18 ] and Rotavin-M1 ® from Polyvac (Center for Research and Production of Vaccines and Biologicals), Hanoi, Vietnam [ 19 ].…”

“…All the LAORoVs are cold-chain storage vaccines, even the cost-effective thermostable RotaSIIL ® best functions in cold storage compared with an ambient storage condition [ 19 , 166 ]. This procedure involves various logistical issues such as storage, transportation, and distribution, which may be difficult to implement in LICs [ 352 , 353 ].…”

“…Over 500,000 doses already rolled out. The vaccine must be stored at −20 • C[19].RV3 is based on a neonatal G3P…”